Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVIR Atea Pharmaceuticals	$2.96 +8.8%	$2.93	$2.60 ▼ $4.15	$253.31M	0.17	305,668 shs	702,984 shs
CARA Cara Therapeutics		$15.19	$8.13 ▼ $31.32	$24.33M	0.41	23,818 shs	237,144 shs
IMAB I-Mab	$0.95 +7.4%	$0.83	$0.60 ▼ $2.00	$77.02M	1.13	308,199 shs	186,671 shs
PGEN Precigen	$1.37 +3.0%	$1.53	$0.65 ▼ $2.17	$404.38M	1.82	1.27 million shs	2.79 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVIR Atea Pharmaceuticals	+8.82%	0.00%	+9.23%	-1.00%	-23.91%
CARA Cara Therapeutics	0.00%	0.00%	+8.57%	+3.30%	-38.05%
IMAB I-Mab	+7.39%	+10.53%	+41.89%	-2.58%	-46.91%
PGEN Precigen	+3.01%	-9.87%	-2.14%	-19.41%	+7.87%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVIR Atea Pharmaceuticals	2.7391 of 5 stars	3.3	3.0	0.0	1.9	2.5	1.3
CARA Cara Therapeutics	3.457 of 5 stars	3.0	5.0	4.2	0.6	0.8	0.0
IMAB I-Mab	2.895 of 5 stars	3.7	3.0	0.0	3.3	1.7	0.6
PGEN Precigen	3.5745 of 5 stars	3.5	0.0	4.7	1.9	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVIR Atea Pharmaceuticals	2.50	Moderate Buy	$6.00	102.70% Upside
CARA Cara Therapeutics	2.00	Hold	$83.52	∞ Upside
IMAB I-Mab	3.33	Buy	$5.50	482.01% Upside
PGEN Precigen	3.00	Buy	$7.00	410.95% Upside

Current Analyst Ratings Breakdown

Latest CARA, IMAB, AVIR, and PGEN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/11/2025	AVIR Atea Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$6.20 ➝ $6.00
4/4/2025	IMAB I-Mab	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $7.00
4/4/2025	IMAB I-Mab	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
3/20/2025	PGEN Precigen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00
3/7/2025	AVIR Atea Pharmaceuticals	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
2/27/2025	IMAB I-Mab	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVIR Atea Pharmaceuticals	N/A	N/A	N/A	N/A	$6.65 per share	N/A
CARA Cara Therapeutics	$7.14M	0.00	N/A	N/A	$12.58 per share	0.00
IMAB I-Mab	$3.27M	23.53	N/A	N/A	$2.93 per share	0.32
PGEN Precigen	$3.93M	103.03	N/A	N/A	$0.48 per share	2.85

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVIR Atea Pharmaceuticals	-$135.96M	-$2.00	N/A	N/A	N/A	N/A	-34.90%	-32.38%	N/A
CARA Cara Therapeutics	-$118.51M	-$21.01	N/A	N/A	N/A	-1,099.76%	-367.97%	-107.43%	N/A
IMAB I-Mab	-$206.44M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
PGEN Precigen	-$95.90M	-$0.48	N/A	N/A	N/A	-3,521.68%	-123.06%	-87.33%	5/13/2025 (Estimated)

Latest CARA, IMAB, AVIR, and PGEN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	PGEN Precigen	-$0.08	N/A	N/A	N/A	$0.50 million	N/A
5/12/2025	Q1 2025	AVIR Atea Pharmaceuticals	-$0.56	-$0.40	+$0.16	-$0.40	N/A	N/A
3/19/2025	Q4 2024	PGEN Precigen	-$0.06	-$0.04	+$0.02	-$0.06	$1.30 million	$1.19 million
3/6/2025	Q4 2024	AVIR Atea Pharmaceuticals	-$0.35	-$0.40	-$0.05	-$0.40	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVIR Atea Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CARA Cara Therapeutics	N/A	N/A	N/A	N/A	N/A
IMAB I-Mab	N/A	N/A	N/A	N/A	N/A
PGEN Precigen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVIR Atea Pharmaceuticals	N/A	19.33	19.33
CARA Cara Therapeutics	N/A	4.77	4.71
IMAB I-Mab	N/A	15.99	15.99
PGEN Precigen	N/A	1.63	1.63

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVIR Atea Pharmaceuticals	86.67%
CARA Cara Therapeutics	44.66%
IMAB I-Mab	38.38%
PGEN Precigen	33.51%

Insider Ownership

Company	Insider Ownership
AVIR Atea Pharmaceuticals	17.80%
CARA Cara Therapeutics	3.10%
IMAB I-Mab	22.10%
PGEN Precigen	44.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVIR Atea Pharmaceuticals	70	85.58 million	69.43 million	Optionable
CARA Cara Therapeutics	80	4.57 million	4.43 million	Optionable
IMAB I-Mab	380	81.50 million	63.49 million	Optionable
PGEN Precigen	190	295.17 million	161.37 million	Optionable

CARA, IMAB, AVIR, and PGEN Headlines

Recent News About These Companies

Precigen (PGEN) to Release Earnings on Tuesday

May 12 at 3:01 AM | americanbankingnews.com

Reviewing Precigen (NASDAQ:PGEN) & Biofrontera (NASDAQ:BFRI)

May 12 at 2:15 AM | americanbankingnews.com

Precigen (PGEN) Expected to Announce Earnings on Tuesday

May 8, 2025 | marketbeat.com

Precigen, Inc. (NASDAQ:PGEN) Shares Sold by Renaissance Technologies LLC

May 2, 2025 | marketbeat.com

Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th

April 16, 2025 | prnewswire.com

Is Precigen (PGEN) The Hot Biotech Stock Under $5?

March 27, 2025 | msn.com

Precigen options imply 20.1% move in share price post-earnings

March 20, 2025 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Precigen (PGEN) and Edwards Lifesciences (EW)

March 20, 2025 | markets.businessinsider.com

4PGEN : Expert Outlook: Precigen Through The Eyes Of 4 Analysts

March 20, 2025 | benzinga.com

Precigen, Inc.: Precigen Reports Full Year 2024 Financial Results and Business Updates

March 20, 2025 | finanznachrichten.de

Precigen Reports Progress and Financial Results for 2024

March 19, 2025 | tipranks.com

Precigen, Inc. (PGEN) Q4 2024 Earnings Call Transcript

March 19, 2025 | seekingalpha.com

Precigen, Inc. (PGEN) Reports Q4 Loss, Lags Revenue Estimates

March 19, 2025 | zacks.com

Precigen Reports Full Year 2024 Financial Results and Business Updates

March 19, 2025 | prnewswire.com

Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th

March 13, 2025 | prnewswire.com

Why Precigen, Inc. (PGEN) is Skyrocketing So Far in 2025

March 1, 2025 | insidermonkey.com

Precigen: UltraCAR-T Development Brings Another Side Of Pipeline Advancement

February 28, 2025 | seekingalpha.com

Precigen shares surge on FDA priority review for PRGN-2012

February 25, 2025 | in.investing.com

Precigen’s BLA for PRGN-2012 in papillomatosis granted priority review by FDA

February 25, 2025 | markets.businessinsider.com

FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025

February 25, 2025 | prnewswire.com

Precigen, Inc. (PGEN) Just Flashed Golden Cross Signal: Do You Buy?

February 20, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CARA, IMAB, AVIR, and PGEN Company Descriptions

Atea Pharmaceuticals NASDAQ:AVIR

$2.96 +0.24 (+8.82%)

Closing price 05/12/2025 04:00 PM Eastern

Extended Trading

$2.89 -0.07 (-2.36%)

As of 05/12/2025 07:29 PM Eastern

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Cara Therapeutics NASDAQ:CARA

Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

I-Mab NASDAQ:IMAB

$0.94 +0.07 (+7.39%)

Closing price 05/12/2025 03:59 PM Eastern

Extended Trading

$0.94 0.00 (-0.21%)

As of 07:20 AM Eastern

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.

Precigen NASDAQ:PGEN

$1.37 +0.04 (+3.01%)

Closing price 05/12/2025 04:00 PM Eastern

Extended Trading

$1.38 +0.01 (+0.73%)

As of 07:58 AM Eastern

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time